These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 114590)
1. Activation of murine complement by cobra venom factor in the presence of EDTA. Goldman JN; Bangalore S; Goldman MB J Immunol; 1979 Nov; 123(5):2421-7. PubMed ID: 114590 [No Abstract] [Full Text] [Related]
2. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex. Miyama A; Kato T; Horai S; Yokoo J; Kashiba S Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074 [TBL] [Abstract][Full Text] [Related]
3. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system. Kitamura H; Tsuboi M; Nagaki K Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147 [TBL] [Abstract][Full Text] [Related]
4. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. II. Physico-chemical characterization of the activated complex. Miyama A; Kato T; Yokoo J; Kashiba S Biken J; 1975 Dec; 18(4):205-14. PubMed ID: 1218075 [TBL] [Abstract][Full Text] [Related]
5. Studies of the alternate pathway in chelated serum. Forsgren A; Mclean RH; Michael AF; Quie PG J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816 [TBL] [Abstract][Full Text] [Related]
6. Identification of functionally relevant determinants on the complement component C3 with monoclonal antibodies. Burger R; Deubel U; Hadding U; Bitter-Suermann D J Immunol; 1982 Nov; 129(5):2042-50. PubMed ID: 6181157 [No Abstract] [Full Text] [Related]
7. Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation. Vogt W; Schmidt G; Hinsch B Immunology; 1979 Jan; 36(1):139-43. PubMed ID: 422225 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of vitamin D2-induced arteriosclerosis in rats by depletion of complement with cobra venom factor. Pang AS; Minta JO Artery; 1980; 7(2):109-22. PubMed ID: 7000037 [TBL] [Abstract][Full Text] [Related]
9. The cobra complement system: I. The alternative pathway of activation. Vogel CW; Müller-Eberhard HJ Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085 [TBL] [Abstract][Full Text] [Related]
10. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes. Lint TF; Behrends CL; Baker PJ; Gewurz H J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985 [TBL] [Abstract][Full Text] [Related]
11. In vivo decomplementation of guinea pigs with cobra venom factor and anti-C3 serum: analysis of the requirement of C3 and C5 for the mediation of endotoxin-induced death. Drake WP; Pokorney DR; Kopyta LP; Mardiney MR Biomedicine; 1976 May; 25(3):91-4. PubMed ID: 949521 [TBL] [Abstract][Full Text] [Related]
12. Activation of factor B and C3 in guinea pig serum by zymosan or by activated properdin depends on the presence of factor D. Brade V; Bentley C; Kossorotow A; Bitter-Suermann D Monogr Allergy; 1977; 12():83-5. PubMed ID: 917024 [No Abstract] [Full Text] [Related]
13. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. Maroko PR; Carpenter CB; Chiariello M; Fishbein MC; Radvany P; Knostman JD; Hale SL J Clin Invest; 1978 Mar; 61(3):661-70. PubMed ID: 641147 [TBL] [Abstract][Full Text] [Related]
14. Purification of a human serum protein ("factor E") which enhances cobra venom factor-induced indirect lysis. Identification with the fifth component of complement. Lynen R; Vogt W; Schmidt G; Dieminger L Z Immunitatsforsch Exp Klin Immunol; 1976 Apr; 151(2):105-16. PubMed ID: 134530 [TBL] [Abstract][Full Text] [Related]
15. Antiglomerular basement membrane nephritis in the mouse. Study on the role of complement in the heterologous phase. Schrijver G; Assmann KJ; Bogman MJ; Robben JC; de Waal RM; Koene RA Lab Invest; 1988 Oct; 59(4):484-91. PubMed ID: 3050274 [TBL] [Abstract][Full Text] [Related]
16. The activation of macrophages by Corynebacterium parvum: effect of anti-complementary agents cobra venom factor and sodium cyanate. Ghaffar A J Reticuloendothel Soc; 1980 Mar; 27(3):327-35. PubMed ID: 7365736 [No Abstract] [Full Text] [Related]
17. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid. Vogt W; Schmidt G; Lynen R; Dieminger L J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510 [TBL] [Abstract][Full Text] [Related]
18. Sheep serum complement sensitisation of sheep erythrocyte-rabbit antibody complexes for haemolysis by guinea-pig complement plus EDTA or Mg2+-EGTA. Jonas W; Stankiewicz M Arch Immunol Ther Exp (Warsz); 1986; 34(4):451-60. PubMed ID: 3099725 [TBL] [Abstract][Full Text] [Related]
19. Human platelet-initiated formation and uptake of the C5-9 complex of human complement. Zimmerman TS; Kolb WP J Clin Invest; 1976 Jan; 57(1):203-11. PubMed ID: 812888 [TBL] [Abstract][Full Text] [Related]
20. The importance of an intact complement pathway in recovery from a primary viral infection: influenza in decomplemented and in C5-deficient mice. Hicks JT; Ennis FA; Kim E; Verbonitz M J Immunol; 1978 Oct; 121(4):1437-45. PubMed ID: 701803 [No Abstract] [Full Text] [Related] [Next] [New Search]